Steminent Biotherapeutics specializes in developing innovative stem cell-based therapeutics that offer new hope for patients ...

“We are pleased with the DSMB’s recommendation, an important step forward in advancing this allogeneic off the shelf mesenchymal stromal/stem cell therapy,” said Peter Altman, BioCardia Chie ...

There have been no treatment emergent major adverse cardiac events observed nor has there been any clinical evidence of immune reactions to the allogeneic cells implanted. “We are pleased with the ...

U.K. Not yet recruiting Prochymal Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-Severe Crohn's Disease Crohn's disease BM-derived allogeneic MSC (Prochymal) OsirisTherapeutics ...

There have been no treatment emergent major adverse ... Dose Comparison Study of Allogeneic Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy (The TRIDENT Study).

NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular ... s proprietary mesenchymal lineage cell therapy technology platform respond ...

Explore the advancements in stem cell therapy for neurodegenerative diseases. Discover market size, trends, and growth projections for 2035 with a focus on treatment innovations.